Fundus Albipunctatus

Fundus Albipunctatus is a rare, inherited eye condition that primarily affects a person's ability to see in low light or darkness, a symptom known as night blindness. People with this condition have numerous tiny, white or yellowish spots scattered across their retina, which is the light-sensitive tissue at the back of the eye. These spots are usually present from childhood and are a key feature that eye doctors look for during an examination. For most people with Fundus Albipunctatus, the night blindness does not get worse over time, and their vision in normal daylight remains good. However, it can take much longer than usual for their eyes to adjust when moving from a bright environment to a dark one. While the condition is generally stable, some individuals may experience a gradual decline in their central, detailed vision or color vision as they get older. The condition is caused by changes (mutations) in specific genes that are responsible for the normal functioning of the retina. It is typically inherited when both parents pass down a copy of the altered gene. Currently, there is no cure, but regular eye exams are important to monitor the health of the retina and manage any changes in vision. Genetic testing can help confirm the diagnosis and provide more information about the specific genetic cause.

Condition category: Stationary Disorder

Prevalence: Very rare

Inheritance patterns: Autosomal Recessive

Age of onset: Childhood

Clinical overview: Fundus Albipunctatus (FA) is a rare, inherited retinal dystrophy characterized by congenital stationary night blindness and the presence of numerous small, white-yellowish lesions scattered throughout the retina, typically sparing the fovea. It belongs to a heterogeneous group of disorders known as flecked retina syndromes. The condition is primarily caused by defects in the visual cycle, leading to delayed dark adaptation. Clinically, patients present with impaired night vision from childhood, while their daytime vision and visual fields often remain normal. A hallmark of the disease is that rod photoreceptor function, as measured by electroretinography (ERG), is initially reduced but can normalize after prolonged periods of dark adaptation. While traditionally considered a stationary disorder, recent evidence suggests that some patients may develop progressive cone dysfunction or macular degeneration later in life. The disorder is most commonly inherited in an autosomal recessive manner, with mutations in the RDH5 gene being the most frequent cause. Other genes, such as RLBP1 and RPE65, have also been implicated. The condition is cataloged under OMIM #136880 and Orphanet #227796. Accurate diagnosis relies on clinical examination, electrophysiology, and genetic testing to differentiate it from other progressive retinal dystrophies.

Patient and family guide: Fundus Albipunctatus is a rare, inherited eye condition that primarily affects a person's ability to see in low light or darkness, a symptom known as night blindness. People with this condition have numerous tiny, white or yellowish spots scattered across their retina, which is the light-sensitive tissue at the back of the eye. These spots are usually present from childhood and are a key feature that eye doctors look for during an examination. For most people with Fundus Albipunctatus, the night blindness does not get worse over time, and their vision in normal daylight remains good. However, it can take much longer than usual for their eyes to adjust when moving from a bright environment to a dark one. While the condition is generally stable, some individuals may experience a gradual decline in their central, detailed vision or color vision as they get older. The condition is caused by changes (mutations) in specific genes that are responsible for the normal functioning of the retina. It is typically inherited when both parents pass down a copy of the altered gene. Currently, there is no cure, but regular eye exams are important to monitor the health of the retina and manage any changes in vision. Genetic testing can help confirm the diagnosis and provide more information about the specific genetic cause.

Symptoms and clinical features: The clinical presentation of Fundus Albipunctatus is primarily characterized by congenital stationary night blindness (nyctalopia). In the early stages, typically during childhood, patients or their parents may notice significant difficulty seeing in low-light conditions or a markedly prolonged time needed to adapt to the dark after being in a bright environment. Despite these symptoms, daytime visual acuity and visual fields are usually normal. Upon clinical examination, the hallmark feature is the presence of numerous discrete, small, round, yellowish-white lesions scattered throughout the mid-peripheral retina. These flecks typically spare the fovea, the central part of the macula responsible for sharp, detailed vision. The optic nerve and retinal blood vessels generally appear normal in the early and intermediate stages of the disease. In advanced stages, while the night blindness often remains stationary, some patients may develop progressive cone dysfunction or macular degeneration. This can manifest as a gradual decline in central visual acuity, color vision abnormalities, and constriction of the visual field. The retinal flecks may change in appearance or distribution, and signs of retinal pigment epithelium (RPE) atrophy may become apparent.

Molecular pathology: The molecular pathology of Fundus Albipunctatus primarily involves defects in the visual cycle, the biochemical pathway responsible for regenerating the visual chromophore, 11-cis-retinal, after light exposure. The most frequently implicated gene, RDH5, encodes 11-cis-retinol dehydrogenase, an enzyme predominantly expressed in the smooth endoplasmic reticulum of the retinal pigment epithelium (RPE). Under normal conditions, 11-cis-retinol dehydrogenase catalyzes the final step of the visual cycle in the RPE, converting 11-cis-retinol to 11-cis-retinal. This chromophore is then transported back to the photoreceptors to combine with opsins, forming functional visual pigments. Mutations in RDH5 disrupt this enzymatic activity, leading to a delayed regeneration of 11-cis-retinal. This delay in chromophore regeneration results in the characteristic prolonged dark adaptation seen in patients. The exact composition of the white-yellowish retinal lesions is not fully understood, but they are thought to represent accumulations of retinoid byproducts or lipid deposits within the RPE due to the impaired visual cycle. Over time, the metabolic stress on the RPE and photoreceptors can lead to cellular dysfunction and, in some cases, progressive retinal degeneration.

Genetics: Fundus Albipunctatus is primarily inherited in an autosomal recessive manner. The most common genetic cause is mutations in the RDH5 gene (OMIM: 601617), which accounts for the majority of cases. The RDH5 gene encodes the 11-cis-retinol dehydrogenase enzyme, which is essential for the visual cycle. Mutations in other genes have also been associated with the condition, including RLBP1 (OMIM: 180090) and RPE65 (OMIM: 180069). RLBP1 encodes the cellular retinaldehyde-binding protein, while RPE65 encodes the isomerase of the visual cycle. Mutations in these genes can lead to overlapping phenotypes, sometimes presenting initially as Fundus Albipunctatus before progressing to more severe retinal dystrophies like retinitis punctata albescens. Genotype-phenotype correlations are complex. While RDH5 mutations typically cause a stationary form of night blindness, some patients, particularly older individuals, may develop progressive cone dystrophy or macular involvement. The specific mutation type and location within the gene may influence the severity and progression of the disease, though environmental factors and genetic modifiers likely also play a role.

Diagnostic evaluation: Clinical diagnosis of Fundus Albipunctatus is based on characteristic fundus findings, electrophysiology, and genetic testing. Fundoscopy reveals numerous discrete, small, round, yellowish-white lesions distributed throughout the mid-peripheral retina, typically sparing the fovea. The optic nerve head and retinal vessels usually appear normal. Optical coherence tomography (OCT) often shows hyperreflective deposits at the level of the retinal pigment epithelium (RPE) corresponding to the white dots seen on fundoscopy. In some cases, structural changes in the outer retina may be observed, particularly if there is associated cone dystrophy or macular involvement. Electrophysiology is crucial for diagnosis. Full-field electroretinography (ERG) typically shows reduced scotopic responses after standard 30-40 minutes of dark adaptation. However, a hallmark of the disease is that these responses usually normalize after prolonged dark adaptation (often 2-3 hours or more). Photopic responses are generally normal, though they may be reduced in patients who develop progressive cone dystrophy. Genetic testing confirms the diagnosis by identifying biallelic pathogenic variants in associated genes, most commonly RDH5. Differential diagnosis includes other flecked retina syndromes such as retinitis punctata albescens (which is typically progressive), fundus flavimaculatus (Stargardt disease), and familial drusen, as well as inflammatory white dot syndromes.

Differential diagnosis: Differential diagnosis of fundus albipunctatus includes: (1) Retinitis punctata albescens — progressive, associated with RP-like degeneration over time. (2) Oguchi disease — golden-yellow fundus sheen (Mizuo-Nakamura phenomenon) rather than white dots. (3) Fleck retina of Kandori — larger, irregular yellow-white flecks, nonprogressive. (4) Drusen (early AMD) — older patients, macular predominance, no delayed dark adaptation. (5) Bietti crystalline dystrophy — crystalline deposits with chorioretinal atrophy. (6) Vitamin A deficiency — reversible white spots, systemic signs.

Natural history: Fundus Albipunctatus typically presents in childhood with non-progressive night blindness (nyctalopia). The characteristic white-yellowish retinal lesions are often present early in life and may remain relatively stable in number and distribution for many years. For most patients, the condition is considered a stationary form of night blindness, meaning the rod dysfunction does not significantly worsen over time. Visual acuity and visual fields usually remain normal under photopic (daylight) conditions. However, long-term follow-up has revealed that a subset of patients, particularly as they age, may develop progressive cone dystrophy or macular degeneration. This can lead to a decline in central visual acuity, color vision abnormalities, and visual field constriction. The rate of this decline is variable and may depend on the specific underlying genetic mutation and other individual factors.

Management and treatment research: ### Current management There is currently no cure for fundus albipunctatus. Care focuses on monitoring vision, managing symptoms, and supporting independence in daily activities. - **Regular eye examinations:** An inherited retinal disease specialist can monitor visual acuity, visual fields, retinal appearance, and retinal function. Many people have relatively stable central vision for years, but some may develop changes affecting cone cells (retinal cells important for detailed and color vision) or the macula, the central part of the retina. - **Support for night-vision difficulty:** Fundus albipunctatus commonly causes delayed dark adaptation, meaning that vision takes longer than usual to adjust after moving from light to darkness. Allowing extra time to adapt, using appropriate lighting, and avoiding driving or other potentially unsafe activities in dim conditions when vision is impaired may help. - **Low-vision rehabilitation:** If central vision, contrast sensitivity, or other visual functions become affected, low-vision services can provide magnifiers, electronic aids, glare-control strategies, and training for school, work, and daily activities. - **Genetic testing and counseling:** Genetic testing can help confirm the diagnosis and identify the responsible gene, often **RDH5**. Results may clarify inheritance patterns, inform family-planning discussions, and help identify research opportunities. ### Approved therapies There are no FDA-approved treatments specifically for fundus albipunctatus. Although gene-based treatments are approved for some other inherited retinal diseases, they are not approved for fundus albipunctatus and may not be appropriate for this condition. ### Investigational therapies Fundus albipunctatus is often linked to changes in genes involved in the retinal visual cycle. The visual cycle is a series of chemical steps that regenerates visual pigment, which is needed for vision in dim light. There are currently no condition-specific treatment candidates listed in the available research pipeline for fundus albipunctatus. #### Gene therapy Gene therapy aims to deliver a working copy of a gene to retinal cells. It is being studied in several inherited retinal diseases, including some conditions involving visual-cycle genes. However, no gene therapy is approved for fundus albipunctatus, and no active interventional gene-therapy trial specific to this condition is listed in the current trial information. #### Pharmacologic and visual-cycle approaches Researchers have explored retinoid-based compounds and other strategies intended to support or bypass parts of the visual cycle. These approaches remain experimental and are not established treatments for fundus albipunctatus. No active condition-specific pharmacologic treatment trials are listed in the available data. ### Clinical trial participation The **Foundation Fighting Blindness Inherited Retinal Degenerative Disease Registry** (**NCT02435940**) is recruiting. This is a registry study rather than a treatment trial. Registries collect information about diagnoses, genetic findings, and disease progression. They may help researchers better understand inherited retinal diseases and may help identify people who could be eligible for future studies. People interested in research participation can discuss genetic testing, eligibility, and practical considerations with their retinal specialist.

Outlook: The overall prognosis for patients with Fundus Albipunctatus is generally favorable compared to many other inherited retinal dystrophies. The night blindness is typically stationary, and most patients maintain good central visual acuity and visual fields throughout their lives under normal lighting conditions. However, the prognosis can be variable. A significant subset of patients may develop progressive cone dystrophy or macular degeneration as they age, which can lead to a decline in central vision and affect quality of life. Regular ophthalmological monitoring is essential to detect and manage these potential complications. Genetic counseling is also recommended to help patients and families understand the inheritance pattern and potential risks.

Epidemiology: Fundus Albipunctatus is a rare genetic disorder, and its exact prevalence is unknown. It has been reported in various populations worldwide, with a higher frequency noted in populations with a high rate of consanguinity. The condition affects both males and females equally, consistent with its autosomal recessive inheritance pattern. While it is considered a rare disease, the increasing availability of genetic testing is helping to better define its true incidence and geographic distribution.

Selected references: 1. Skorczyk-Werner A, Pawłowski P, Michalczuk M, Warowicka A, Wawrocka A, Wicher K, Bakunowicz-Łazarczyk A, Krawczyński MR. Fundus albipunctatus: review of the literature and report of a novel RDH5 gene mutation affecting the invariant tyrosine (p.Tyr175Phe). J Appl Genet. 2015;56(3):317-327. PMID: 25820994 2. Khan R, Channa J, Wang H. Genetic Basis of Retinitis Punctata Albescens (RPA) and Fundus Albipunctatus (FA): Overlapping Phenotypes and Diagnostic Approaches. JSM Ophthalmol. 2026;13(1):1099. 3. Yamamoto H, Simon A, Eriksson U, Harris E, Berson EL, Dryja TP. Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nat Genet. 1999;22(2):188-191. PMID: 10369264 4. Nakamura M, Hotta Y, Tanikawa A, Terasaki H, Miyake Y. A high association with cone dystrophy in Fundus albipunctatus caused by mutations of the RDH5 gene. Invest Ophthalmol Vis Sci. 2000;41(12):3925-3932. PMID: 11053295 5. Katsanis N, Shroyer NF, Lewis RA, Cavender JC, Al-Rajhi AA, Jabak M, Lupski JR. Fundus albipunctatus and retinitis punctata albescens in a pedigree with an R150Q mutation in RLBP1. Clin Genet. 2001;59(6):424-429. PMID: 11453974